ClinicalTrials.gg
CompletedNCT00833027Updated May 15, 2017Results posted

ALPHA Sitagliptin Add on to Metformin (0431-103)

A Phase 4 interventional study of sitagliptin phosphate in Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Mar 2008, registered Jan 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
608
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing sitagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. sitagliptin · Diabetes Mellitus.

Enrollment
2nd of 58
608 · median 45
Started
2008
with 10 others
Phase 4
29 of 58
none open now
Registered
15th of 58
by date
Lead sponsor
3 of 58
Merck Sharp & Dohme LLC

Among the 58 studies testing sitagliptin in Diabetes Mellitus, this one is the 2nd largest by enrollment, is one of 11 that started in 2008, is one of 29 in phase 4, and was the 15th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 58 studies testing sitagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 58 studies testing sitagliptin in Diabetes Mellitus as a file.
02

Study summary

Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Patient Is Currently On Monotherapy With Metformin For At Least 10 Weeks Prior To Study Entry

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
608 participants (actual)

Study arms

  • Experimental
    1

    Sitagliptin

    Drug: sitagliptin phosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c at Week 24

    HbA1c is measured as percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in HbA1c at Week 12

    HbA1c is measured as percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent

    Time frame: Baseline and Week 12

07

Results

Posted Sep 21, 2010

Participant flow

First patient in: 11-MAR-2008 Last patient out: 30-OCT-2009 Total number of sites: 110

Participant flow — Overall Study
MilestoneSitagliptin 100mg
Started608
Completed397
Not completed211
Withdrew: Adverse event33
Withdrew: Death1
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up24
Withdrew: Protocol violation115
Withdrew: Withdrawal by subject16
Withdrew: Missing10

Outcome measures

PrimaryChange From Baseline in HbA1c at Week 24

HbA1c is measured as percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent
Change From Baseline in HbA1c at Week 24
PercentSitagliptin 100mg
Change From Baseline in HbA1c at Week 24-0.6 ± 0.95
Statistical analysis
  • Sitagliptin 100mg · Student's T-test · p = <0.001 · Mean difference (net): -0.6Student's T-test for paired samples
SecondaryChange From Baseline in HbA1c at Week 12

HbA1c is measured as percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent

Time frame:
Baseline and Week 12
Reported as:
Mean · Percent
Change From Baseline in HbA1c at Week 12
PercentSitagliptin 100mg
Change From Baseline in HbA1c at Week 12-0.6 ± 0.85

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100mg—17/608 (2.8%)0/608 (0%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventSitagliptin 100mg
Chest painGeneral disorders3/608
DepressionPsychiatric disorders3/608
Acute coronary syndromeCardiac disorders2/608
Cardiac failure congestiveCardiac disorders1/608
Cardiac tamponadeCardiac disorders1/608
Myocardial infarctionCardiac disorders1/608
GastritisGastrointestinal disorders1/608
Inguinal hernia, obstructiveGastrointestinal disorders1/608
Sudden deathGeneral disorders1/608
GastroenteritisInfections and infestations1/608

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100mg
Mean58.0 ± 11.23
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100mg
Female258
Male350
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sitagliptin 100mg
Caucasian491
Black16
Hispanic6
Asian73
Native Indian6
Other16
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(percent)Sitagliptin 100mg
Mean7.73 ± 1.11
Weight
Weight(Kilograms)Sitagliptin 100mg
Mean92.6 ± 24.42
Fasting plasma glucose
Fasting plasma glucose(mmol/L)Sitagliptin 100mg
Mean9.3 ± 2.87
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2008 to primary completion in Oct 2009, 19 months.

Results were first posted in Sep 2010, 10 months after primary completion.

Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 19 months is above that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2009
First posted
Jan 30, 2009
StartActual
Mar 1, 2008
Primary completionActual
Oct 30, 2009
CompletionActual
Oct 30, 2009
Results first posted
Sep 21, 2010
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00833027
Responsible party
Sponsor
First posted
Jan 30, 2009
Start date
Mar 1, 2008
Primary completion
Oct 30, 2009
Completion
Oct 30, 2009
Results posted
Sep 21, 2010
Last update
May 15, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion